Choose a Topic
- All Topics
- ASH 2017
- AML
- MDS
- Lymphomas and CLL
- Older Patient HCT
- Sickle Cell Disease
- Post-Transplant
- GVHD
- Patient Eligibility
- CIBMTR Publications
- Cord Blood
- Pediatric HCT
- ALL
- CML
- Multiple Myeloma
- Neuroblastoma
- Non-Malignant Disorders
- HLA Matching
- Preparative Regimens
- BMT CTN Publications
- Unrelated Donor HCT
- ASH 2018
- ASH 2020
Recent Research
Stay up-to-date on the advancing field of HCT with short summaries and links to the most relevant published research.
Bolaños-Meade J, et al., The Lancet Haematology – In a prospective, phase II trial, researchers found that tacrolimus, mycophenolate mofetil, with post-hematopoietic cell transplant (HCT) cyclophosphamide (TMMCy) produced the best GVHD-free, relapse-free survival (GRFS) for patients who received an allogeneic HCT when compared to the current standard of care.